Please login to the form below

Not currently logged in
Email:
Password:

Linzess

This page shows the latest Linzess news and features for those working in and with pharma, biotech and healthcare.

NICE backs Allergan's IBS therapy Truberzi

NICE backs Allergan's IBS therapy Truberzi

includes Linzess (linaclotide) for IBS with constipation. ... Viberzi sales in the US were almost $73m in the first six months of the year, almost a three-fold increase over the same period a year earlier, while Linzess contributed

Latest news

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome. ... All eyes will now be on the performance

  • Pharma deals during April 2014 Pharma deals during April 2014

    Forest is building a leading position in the $38bn gastroenterology (GI) market adding eluxadoline to its broader GI portfolio including Linzess.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Ironwood appoints Edward Owens to board Ironwood appoints Edward Owens to board

    Owens is a former partner at investments advisor Wellington Management, and joins the US-based biopharma at a time of growth following the approval of Linzess (linaclotide) in the US for ... The execution of a successful launch of Linzess should provide

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera

We live in a time of participation – patients actively involved in their own care recover faster and live longer....

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics